JNJ Overview
Upcoming Projects (JNJ)
Executed Projects (JNJ)
-
Discussing the updated data for Cretostimogene Grenadenorapvec and TAR-200 for BCG-unresponsive NMIBC presented at AUA
Tickers: CGON, JNJ
Executed On: Apr 29, 2025 at 05:30 PM EDT -
Discussing the NMIBC landscape with a focus on CG Oncology's Cretostimogene Grenadenorepvec
Tickers: CGON, JNJ, TNREF, URGN
Executed On: Apr 11, 2025 at 10:00 AM EDT -
Discussing recent updates in the menin inhibitor landscape with a focus on Revuforj, enzomenib, and bleximenib
Tickers: SNDX, KURA, JNJ, DNPUF
Executed On: Feb 06, 2025 at 02:00 PM EST -
Quarterly Survey: Benign Prostatic Hyperplasia (BPH) procedures January 2025
Tickers: TFX, PRCT, ISRG, JNJ
Executed On: Jan 27, 2025 at 12:04 PM EST -
Quarterly Survey: Breast Augmentation Procedures and Implant Preferences January 2025
Tickers: ESTA, ABBV, JNJ, SIEN
Executed On: Jan 23, 2025 at 12:31 PM EST -
A Second Opinion: Discussing the recent decision by JNJ to pause their Varipulse Pulsed Field Ablation system rollout due to stroke risk in patients with Atrial Fibrillation
Tickers: JNJ, BSX, MDT, ABT
Executed On: Jan 17, 2025 at 03:30 PM EST -
Discussing the recent decision by JNJ to pause their Varipulse Pulsed Field Ablation system rollout due to stroke risk in patients with Atrial Fibrillation
Tickers: JNJ, BSX, MDT, ABT
Executed On: Jan 17, 2025 at 11:00 AM EST -
A look at the results from the Phase 3 ICONIC-LEAD study of icotrokinra (JNJ-2113) in patients 12 years of age and older with moderate to severe plaque psoriasis.
Tickers: JNJ, PTGX
Executed On: Jan 14, 2025 at 03:00 PM EST -
A Second Opinion: Looking at the new results from the Phase 3 CARTITUDE-4 study of CARVYKTI presented at ASH2024, as well as the Phase II iMMagin data on Anito-Cel from Gilead/Arcellx
Tickers: JNJ, GILD, ACLX, LEGN
Executed On: Jan 09, 2025 at 04:30 PM EST -
Looking at the new results from the Phase 3 CARTITUDE-4 study of CARVYKTI presented at ASH2024, as well as the Phase II iMMagin data on Anito-Cel from Gilead/Arcellx
Tickers: JNJ, GILD, ACLX, LEGN
Executed On: Jan 09, 2025 at 11:00 AM EST -
Quarterly Survey: Benign Prostatic Hyperplasia (BPH) procedures October 2024
Tickers: TFX, PRCT, ISRG, JNJ
Executed On: Oct 29, 2024 at 01:31 PM EDT -
Quarterly Survey: Breast Augmentation Procedures and Implant Preferences October 2024
Tickers: ABBV, ESTA, JNJ, SIEN
Executed On: Oct 24, 2024 at 05:34 PM EDT -
A Second Viewpoint: Investigating the Phase 3 Vivacity-MG3 clinical trial data on Nipocalimab in patients with myasthenia gravis.
Ticker: JNJ
Executed On: Oct 02, 2024 at 10:00 AM EDT -
A Second Opinion: Reviewing Johnson & Johnson's Velys Spine, a surgical robot and standalone navigation platform for spine surgeries
Tickers: JNJ, SYK, MDT, GMED
Executed On: Aug 28, 2024 at 04:05 PM EDT -
Reviewing Johnson & Johnson's Velys Spine, a surgical robot and standalone navigation platform for spine surgeries
Tickers: JNJ, SYK, MDT, GMED
Executed On: Aug 14, 2024 at 04:00 PM EDT -
Investigating the Phase 3 Vivacity-MG3 clinical trial data on Nipocalimab in patients with myasthenia gravis.
Ticker: JNJ
Executed On: Aug 09, 2024 at 10:00 AM EDT -
Quarterly Survey: Benign Prostatic Hyperplasia (BPH) procedures July 2024
Tickers: PRCT, TFX, ISRG, JNJ
Executed On: Aug 06, 2024 at 04:46 PM EDT -
Quarterly Survey: Breast Augmentation Procedures and Implant Preferences July 2024
Tickers: ABBV, ESTA, JNJ, SIEN
Executed On: Jul 26, 2024 at 12:24 PM EDT -
A Second Look: Discussing recent updates from EHA on menin inhibitors, including DSP-5336, JNJ-6617 in combo with Ven/Aza in r/r AML, and revumenib with the same combo but in newly diagnosed AML.
Tickers: KURA, JNJ, SNDX
Executed On: Jul 17, 2024 at 11:00 AM EDT -
A second look at novel therapeutics in development for NMIBC, including; Cretostimogene, TAR-200, TAR-210 Erdafitinib Intravesical Delivery System, and UGN-102
Tickers: CGON, JNJ, URGN
Executed On: Jun 25, 2024 at 11:00 AM EDT -
Discussing recent updates from EHA on menin inhibitors, including DSP-5336, JNJ-6617 in combo with Ven/Aza in r/r AML, and revumenib with the same combo but in newly diagnosed AML.
Tickers: JNJ, SNDX, KURA
Executed On: Jun 25, 2024 at 09:30 AM EDT -
A Second Look: Discussing a physician's experience using the FaraPulse and PulseSelect PFA systems for atrial fibrillation ablation procedures
Tickers: BSX, MDT, ABT, JNJ
Executed On: Jun 14, 2024 at 08:00 AM EDT -
Discussing a physician's experience using the FaraPulse and PulseSelect PFA systems for atrial fibrillation ablation procedures
Tickers: BSX, MDT, ABT, JNJ
Executed On: Jun 13, 2024 at 05:00 PM EDT -
A look at novel therapeutics in development for NMIBC, including; Cretostimogene, TAR-200 and the TAR-210 Erdafitinib Intravesical Delivery System.
Tickers: CGON, JNJ
Executed On: Jun 06, 2024 at 05:00 PM EDT -
Quarterly Survey: Breast Augmentation Procedures and Implant Preferences April 2024
Tickers: ESTA, ABBV, JNJ, SIEN
Executed On: May 01, 2024 at 11:05 AM EDT -
Quarterly Survey: Benign Prostatic Hyperplasia (BPH) procedures April 2024
Tickers: TFX, PRCT, ISRG, JNJ
Executed On: Apr 18, 2024 at 04:27 PM EDT -
Discussing the recent data on Carvykti and the state of CAR-T therapies in use for multiple myeloma.
Ticker: JNJ
Executed On: Mar 19, 2024 at 09:00 AM EDT -
Looking at the potential of Biosense Webster's Pulsed Field Ablation (PFA) Varipulse system and how it compares to systems from Medtronic and Boston Scientific
Tickers: JNJ, BSX, MDT, ABT
Executed On: Mar 14, 2024 at 05:00 PM EDT -
Quarterly Survey: Breast Augmentation Procedures and Implant Preferences January 2024
Tickers: ESTA, ABBV, JNJ, SIEN
Executed On: Jan 24, 2024 at 12:43 PM EST -
Quarterly Survey: Benign Prostatic Hyperplasia (BPH) procedures January 2024
Tickers: TFX, PRCT, ISRG, JNJ
Executed On: Jan 23, 2024 at 04:28 PM EST -
A Second View: Looking at the recent launch of Olympus Corps next-generation EVIS X1 endoscopy system
Tickers: OLYMY, SYK, BSX, JNJ, SNN, MDT, fujifilm, Pentax Medical
Executed On: Nov 20, 2023 at 04:00 PM EST -
Looking at the recent launch of Olympus Corps next-generation EVIS X1 endoscopy system
Tickers: OLYMY, SYK, BSX, JNJ, SNN, MDT, fujifilm, Pentax Medical
Executed On: Nov 10, 2023 at 05:00 PM EST -
Discussing the MARIPOSA & PAPILLON data for J&J's RYBREVANT (amivantamab-vmjw) in EGFR-mutated lung cancer presented at ESMO 2023
Tickers: JNJ, AMGN
Executed On: Nov 06, 2023 at 01:00 PM EST -
Quarterly Survey: Breast Augmentation Procedures and Implant Trends/Preferences October 2023
Tickers: ABBV, JNJ, SIEN, ESTA
Executed On: Oct 31, 2023 at 11:28 AM EDT -
Quarterly Survey: Benign Prostatic Hyperplasia (BPH) procedures - October 2023
Tickers: TFX, PRCT, JNJ, ISRG
Executed On: Oct 26, 2023 at 02:43 PM EDT -
A Second Look: Reviewing the recent FDA approval of Boston Scientific's POLARx cryoablation system for atrial fibrillation
Tickers: BSX, MDT, JNJ
Executed On: Aug 17, 2023 at 11:30 AM EDT -
Reviewing the recent FDA approval of Boston Scientific's POLARx cryoablation system for atrial fibrillation
Tickers: BSX, MDT, JNJ
Executed On: Aug 16, 2023 at 10:30 AM EDT -
A Second Opinion: Reviewing the use of Mapping Catheters for Cardiac Arrhythmia procedures with a focus on the newly approved Optrell Catheter from Johnson & Johnson
Tickers: JNJ, ABT, MDT
Executed On: Aug 10, 2023 at 12:30 PM EDT -
Reviewing the use of Mapping Catheters for Cardiac Arrhythmia procedures with a focus on the newly approved Optrell Catheter from Johnson & Johnson
Tickers: JNJ, ABT, MDT
Executed On: Aug 03, 2023 at 05:00 PM EDT -
Reviewing the results of Johnson & Johnson's SunRIse-1 trial for patients with Non-Muscle-Invasive Bladder Cancer
Ticker: JNJ
Executed On: Aug 03, 2023 at 09:00 AM EDT -
Quarterly Survey: Breast Augmentation Procedures and Implant Trends/Preferences July 2023
Tickers: ABBV, JNJ, SIEN, ESTA
Executed On: Aug 02, 2023 at 10:52 AM EDT -
A Second Look: Discussing the potential use of Pulsed Field Ablation devices for the treatment of patients with Atrial Fibrillation.
Tickers: MDT, BSX, ABT, JNJ
Executed On: Jul 14, 2023 at 09:00 AM EDT -
Examining the topline results from the Phase 2b FRONTIER 1 clinical trial of Johnson & Johnson's JNJ-2113 in patients with Plaque Psoriasis.
Tickers: JNJ, ABBV
Executed On: Jul 13, 2023 at 11:00 AM EDT -
Discussing various agents targeting BCMA and GPRC5D in multiple myeloma
Tickers: JNJ, LEGN, BMY
Executed On: Jul 12, 2023 at 06:00 PM EDT -
Discussing the potential use of Pulsed Field Ablation devices for the treatment of patients with Atrial Fibrillation.
Tickers: BSX, MDT, ABT, JNJ
Executed On: Jun 27, 2023 at 12:00 PM EDT -
A Second View: Discussing the use of ophthalmic viscosurgical devices (OVD) during cataract surgery, specifically the StableVisc cohesive and TotalVisc Viscoelastic System
Tickers: BLCO, ALC, JNJ
Executed On: Jun 14, 2023 at 06:30 PM EDT -
Quarterly Survey: Breast Implants April 2023
Tickers: JNJ, SIEN, ABBV
Executed On: Apr 14, 2023 at 03:38 PM EDT -
Quarterly Survey: Breast Implants February 2023
Tickers: JNJ, SIEN, ABBV
Executed On: Feb 07, 2023 at 06:12 PM EST -
A Second View: Examining Addex Therapeutics' ADX71149/JNJ-40411813 in combination with Levetiracetam or Brivaracetam in patients with Epilepsy
Tickers: ADXN, JNJ
Executed On: Feb 03, 2023 at 04:00 PM EST -
Examining Addex Therapeutics' ADX71149/JNJ-40411813 in combination with Levetiracetam or Brivaracetam in patients with Epilepsy
Tickers: ADXN, JNJ
Executed On: Feb 02, 2023 at 03:50 PM EST -
Discussing the potential of PARP-inhibitor, Lynparza (olaparib), in combination with abiraterone for patients with mCRPC
Tickers: AZN, JNJ, SUNPHARMA.XBOM
Executed On: Nov 01, 2022 at 11:00 AM EDT -
A look at the use of ELIQUIS, Xarelto, and other blood thinners for cardiovascular disease and atrial fibrillation
Tickers: BMY, JNJ
Executed On: Aug 25, 2022 at 02:00 PM EDT
Expired Projects (JNJ)
-
Discussing the clinical landscape of multiple myeloma with a focus on BCMA CAR-T
Tickers: LEGN, JNJ, TSVT, BMY
Execute By: Oct 31, 2023 -
Discussing various modalities for BCMA targeted therapy in multiple myeloma
Tickers: JNJ, LEGN, BMY
Execute By: Oct 27, 2023 -
Discussing recent advancements in dermatology, with a focus on AD and psoriasis
Tickers: LEGN, BMY, JNJ
Execute By: Oct 27, 2023
Upcoming & Overdue Catalysts (JNJ)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (JNJ)
-
Nine-Month Data Released from MeiraGTx (MGTX) and J&J (JNJ) Phase 1/2 Trial of AAV-RPGR in X-Linked Retinitis Pigmentosa (XLRP)
Tickers: MGTX, JNJ
Occurred on: Oct 03, 2020 -
EU in talks with Moderna, BioNtech, Sanofi, Johnson & Johnson and CureVac to secure possible COVID vaccines
Tickers: JNJ, SNY, BNTX, MRNA
Occurred on: Jul 17, 2020 -
Aduro Biotech (ADRO) expected to initiate Phase 1b/2 trial of ADU-214/JNJ-64041757 in lung cancer in 2017 (Partnership with Janssen)
Tickers: ADRO, JNJ
Occurred on: Jun 07, 2018 -
Johnson & Johnson (JNJ) expects to launch Phase III data on esketamine, an antidepressant, by late 2017
Ticker: JNJ
Occurred on: Apr 18, 2018 -
3½-Year Follow-Up Data of IMBRUVICA (ibrutinib) in Patients with Relapsed/Refractory Mantle Cell Lymphoma
Ticker: JNJ
Occurred on: Dec 09, 2017 -
Johnson & Johnson (JNJ) to report first quarter earnings results in Investor Conference Call on April 18th, 2017
Ticker: JNJ
Occurred on: Apr 18, 2017 -
Johnson & Johnson (JNJ) Phase 2 study shows data of Guselkumab versus Humira in treating moderate to severe plaque psoriasis
Ticker: JNJ
Occurred on: Mar 03, 2017 -
Johnson & Johnson (JNJ) launches new data of Stelara treating adults with moderate to severe active Crohn's disease
Ticker: JNJ
Occurred on: Feb 17, 2017 -
Viiv Healthcare Presents Results from 2 Phase 3 Studies Evaluating Dolutegravir + Rilpivirine in HIV Maintenance
Tickers: VIIV HEALTHCARE, PFE, JNJ, GSK, SGIOF
Occurred on: Dec 20, 2016 -
Janssen (JNJ) Submits Marketing Application in Japan for Darzalex in Multiple Myeloma
Tickers: JNJ, GNMSF
Occurred on: Dec 20, 2016 -
JNJ subsidiary Janssen files FDA application for approval of Guselkumab for treating moderate to severe plaque psoriasis
Ticker: JNJ
Occurred on: Nov 25, 2016 -
PDUFA Date of February 17, 2017 for Janssen's (JNJ) Daratumumab in Relapsed Multiple Myeloma
Ticker: JNJ
Occurred on: Nov 21, 2016 -
Janssen's (JNJ) Stelara Approved by European Commission for Adults with Moderately to Severely Active Crohn's Disease
Tickers: JNJ, Janssen Biotech
Occurred on: Nov 11, 2016 -
Regeneron (REGN) and Sanofi's (SNY) Sarilumab for Rheumatoid Arthritis Granted PDUFA date of October 30, 2016 by FDA
Tickers: REGN, JNJ, SNY, GSK
Occurred on: Oct 28, 2016 -
PDUFA for Stelara (ustekinumab) Adult patients with moderate-to-severe Crohn's set for Sept 2016
Ticker: JNJ
Occurred on: Sep 26, 2016 -
GlaxoSmithKline (GSK) and Johnson & Johnson (JNJ) Plan to Submit Application to FDA in 2016 for Sirukumab in Rheumatoid Arthritis
Tickers: GSK, REGN, SNY, JNJ
Occurred on: Sep 23, 2016 -
FDA Approves Janssen's (JNJ) INVOKAMET XR in Treatment of Adults with Type 2 Diabetes
Ticker: JNJ
Occurred on: Sep 21, 2016 -
Janssen's (JNJ) Stelara Recommended for Approval by European Ad Comm for Treatment of Crohn's Disease
Ticker: JNJ
Occurred on: Sep 16, 2016 -
Johnson & Johnson (JNJ) Announces $4.325B Cash Deal to Acquire Abbott's (ABT) Medical Optics Business
Tickers: JNJ, ABT
Occurred on: Sep 16, 2016 -
GlaxoSmithKline (GSK) and Johnson & Johnson (JNJ) Submit Sirukumab in Treatment of Rheumatoid Arthritis to European Medicines Agency
Tickers: GSK, JNJ, SNY, REGN
Occurred on: Sep 12, 2016 -
Janssen Submits Application to U.S. FDA to Expand Indication for Daratumumab (DARZALEX)
Ticker: JNJ
Occurred on: Aug 17, 2016 -
U.S. FDA Approves PREZISTA (darunavir) for Use in Pregnant Women with HIV
Ticker: JNJ
Occurred on: Jul 18, 2016 -
Simponi Receives European Comission Approval for Treatment of Polyarticular Juvenile Idiopathic Arthritis
Ticker: JNJ
Occurred on: Jun 30, 2016 -
FDA Expands IMBRUVICA Label to Include New Data from Two Key Phase 3 Trials, Adding Overall Survival and Combination Data
Ticker: JNJ
Occurred on: May 09, 2016 -
Janssen to Unveil New Hepatitis B and C Data at The International Liver Congress
Ticker: JNJ
Occurred on: Apr 14, 2016 -
Interim Analysis of Phase 3 Trial of Daratumumab Meets Primary Endpoint of Efficacy and Safety in Treating Multiple Myeloma
Ticker: JNJ
Occurred on: Mar 30, 2016 -
U.S. FDA Approves IMBRUVICA (ibrutinib) for First-line Treatment of Chronic Lymphocytic Leukemia
Tickers: JNJ, ABBV, Janssen Biotech
Occurred on: Mar 04, 2016 -
FDA Approves Odefsey for Treatment of HIV-1
Tickers: GILD, JNJ
Occurred on: Mar 01, 2016 -
First Regimen Combining Long Acting Injectable Antiretrovirals; 32-Week LATTE 2 Study Results Presented at CROI
Ticker: JNJ
Occurred on: Feb 23, 2016 -
FDA’s Arthritis Advisory Committee Recommends Approval of Celltrion’s CT-P13, a Proposed Biosimilar Infliximab, for All Eligible Indications
Tickers: CELLTRION, PFE, MRK, JNJ
Occurred on: Feb 10, 2016 -
FDA reviewers support Celltrion's biosimilar Remicade, ahead of the Ad Comm meeting on February 9
Tickers: CELLTRION, PFE, JNJ, MRK
Occurred on: Feb 05, 2016 -
Janssen has entered into a Definitive Collaboration and License agreement with Bavarian Nordic to Develop Vaccine for Chronic HPV Infections
Tickers: JNJ, BAVA.F
Occurred on: Dec 18, 2015 -
Janssen's (JNJ) Yondelis for Soft Tissue Sarcomas Approved By FDA
Ticker: JNJ
Occurred on: Oct 23, 2015 -
Janssen's (JNJ) STELARA Successful in Phase 3 Chrone's Study
Tickers: JNJ, CELG
Occurred on: Oct 19, 2015
Strategic Initiatives (JNJ)
-
Johnson & Johnson (JNJ) Swiss subsidiary, Janssen, published all-cash public tender offer in Switzerland to acquire all publicly held shares of Actelion.
Tickers: JNJ, ATLNEE.SW
Announcement Date: Mar 31, 2017 -
JNJ's Ethicon Unit Acquires Private Torax Medical for Undisclosed Sum
Tickers: JNJ, Ethicon, Torax Medical
Announcement Date: Feb 20, 2017 -
Janssen's (JNJ) Codman Neurosurgery Business Acquired by Integra (IART) for $1.045B in Cash
Tickers: IART, JNJ, Janssen Biotech
Announcement Date: Feb 15, 2017 -
Akebia Therapeutics (AKBA) Announces Exclusive License Agreement with Janssen Pharma (JNJ) for Portfolio Targeting Hypoxia-Inducible Factors (HIF)
Tickers: AKBA, JNJ
Announcement Date: Feb 13, 2017 -
Renova Therapeutics Acquires IND Filing for Heart Failure Candidate Stesscopin from Janssen Pharmaceuticals (JNJ) for Undisclosed Amount
Tickers: JNJ, Renova Therapeutics
Announcement Date: Feb 06, 2017 -
Amgen (AMGN) and Janssen (JNJ) Announce Collaboration Deal to Evaluate Kyprolis and Darzalex in Multiple Myeloma
Tickers: AMGN, JNJ
Announcement Date: Nov 10, 2016 -
TRACON (TCON) and Janssen (JNJ) Announce Strategic Licensing Collaboration for TRC253 in Treatment of Prostate Cancer and TRC694 in Treatment of Hematologic Malignancies
Tickers: JNJ, TCON
Announcement Date: Sep 28, 2016 -
Janssen Announces Clinical Collaboration with Bristol-Myers Squibb to Evaluate Immuno-oncology Combination in Lung Cancer
Tickers: JNJ, BMY
Announcement Date: Jul 26, 2016 -
Johnson & Johnson buys dermocosmetics firm NeoStrata Company
Tickers: JNJ, NeoStrata Company
Announcement Date: Apr 26, 2016 -
Ethicon Announces Agreement To Acquire NeuWave Medical
Ticker: JNJ
Announcement Date: Mar 07, 2016 -
Johnson & Johnson Announces Actions To Strengthen Medical Devices Leadership Position In Evolving Healthcare Marketplace
Ticker: JNJ
Announcement Date: Jan 19, 2016 -
Enterome enters collaboration with Johnson & Johnson Innovation, focused on the discovery of novel targets and therapeutics for Crohn’s disease
Ticker: JNJ
Announcement Date: Jan 07, 2016
